home / stock / amrx / amrx news

AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 05/03/24

Stock Information
Company Name: Amneal Pharmaceuticals Inc. Class A
Stock Symbol: AMRX
Market: NYSE
Menu
AMRX AMRX Quote AMRX Short AMRX News AMRX Articles AMRX Message Board
Get AMRX Alerts

News, Short Squeeze, Breakout and More Instantly...
AMRX - Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $659M beats by $39.97M

2024-05-03 06:02:55 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Amneal Pharmaceuticals Q1 2024 Earnings Preview FDA approves...
AMRX - Amneal Reports First Quarter 2024 Financial Results

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement...

AMRX - Amneal Pharmaceuticals Q1 2024 Earnings Preview

2024-05-02 11:48:35 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation FDA approves Amneal's generic version of OTC Narcan Bausch H...

AMRX - EDIT, CLNE and NIU are among after hour movers

2024-04-26 17:00:42 ET Gainers: Heartland Financial USA ( HTLF ) +9% . Accolade ( ACCD ) +6% . Editas Medicine ( EDIT ) +4% . Nextracker ( NXT ) +3% . Clean Energy Fuels ( CLNE ) +2% . Losers: Vitru  ( VTRU ) -...
AMRX - FDA approves Amneal's generic version of OTC Narcan

2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...

AMRX - Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Company launches generic equivalent to OTC NARCAN ® Nasal Spray Provides convenient, affordable access to life-saving medicine Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over th...

AMRX - Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forw...
AMRX - Amneal to Report First Quarter 2024 Results on May 3, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Th...

AMRX - Bausch Health drops after suing Amneal Pharma over Xifaxan generic

2024-04-08 15:32:37 ET More on Bausch Health Companies Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Bausch Health Companies (BHC) Q4 2023 Earnings Call Transcript Bausch Health sues Amneal Pharma over Xifaxan generic Bausch Health Com...

AMRX - Bausch Health sues Amneal Pharma over Xifaxan generic

2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...
Previous 10 Next 10